The techniques developed for measuring the fraction of hypoxic cells in animal tumours, and their reoxygenation during a course of radiotherapy, are not of routine clinical use because they are invasive and/ or destructive (Chapman et al., 1981) .
A property of hypoxic cell radiosensitizers (Adams, 1973) , which might be exploited for the detection of hypoxia within solid tumours, is that nitroaromatic drugs become covalently bound to the macromolecules of hypoxic cells by metabolism-induced (McCalla et al., 1970) and radiation-induced (Chapman et al., 1972) (Chapman, 1979; Chapman et al., 1979 ) is now more feasible. By labelling an appropriate hypoxic cell sensitizer (ideally with a serum half-life in man < 5 h) with an appropriate y-emitting radionuclide (e.g. 77Br, half-life 57 h) a nuclear-medicine assay for determining the extent and location of hypoxia within tumour treatment volumes of individual patients might be possible. Patients would be administered the labelled sensitizer during workup, and scanned at least 2 days later to determine the location and extent of retained activity. Such a clinical assay would provide information which could have a significant impact on diagnosis and treatment design. 
